Current Technologies for Sub-Micrometer and Micrometer Particle Analysis for Biologics
Posted on June 22, 2017
Andrea Hawe, Chief Scientific Officer
Coriolis Pharma Research
Daniel Weinbuch, Manager Good Research Practice
Coriolis Pharma Research
Introduction Analyzing and controlling the particle content in biopharmaceutical drug products is a challenge scientists must face throughout a product’s life cycle starting at early drug research, during drug product development, manufacturing and storage. Particles can hereby originate from the ...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
Andrea Hawe, biologics, biopharmaceutical drug products, Coriolis Pharma, CQAs, critical quality attributes, Daniel Weinbuch, degraded polysorbate, drug substance, DS, extrinsic particles, light obscuration, LO, micrometer analysis, micrometer particle analysis, nanoparticulate impurities, Narhi, particle content, protein aggregates, sub micrometer, sugar excipients
Related Products
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
